GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) CEO Joshua Ofman sold 5,000 shares of GRAIL stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $85.02, for a total transaction of $425,100.00. Following the transaction, the chief executive officer owned 397,271 shares of the company's stock, valued at approximately $33,775,980.42. The trade was a 1.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
GRAIL Price Performance
Shares of NASDAQ GRAL opened at $79.37 on Tuesday. The firm's 50-day moving average is $71.28 and its two-hundred day moving average is $63.22. The company has a market capitalization of $3.55 billion, a PE ratio of -8.14 and a beta of 3.24. GRAIL, Inc. has a 12-month low of $30.82 and a 12-month high of $118.84.
GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, topping analysts' consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million during the quarter, compared to analysts' expectations of $42.39 million. On average, analysts forecast that GRAIL, Inc. will post -10.41 EPS for the current fiscal year.
Hedge Funds Weigh In On GRAIL
Several institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its holdings in GRAIL by 17.7% in the first quarter. Royal Bank of Canada now owns 88,082 shares of the company's stock valued at $2,250,000 after acquiring an additional 13,264 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company's stock valued at $76,000 after buying an additional 623 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock valued at $45,000 after buying an additional 1,401 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of GRAIL by 37.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company's stock worth $2,362,000 after buying an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of GRAIL by 115.7% in the second quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company's stock worth $4,090,000 after buying an additional 42,675 shares during the last quarter.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on GRAL. Robert W. Baird set a $70.00 price target on GRAIL in a report on Wednesday, May 6th. Mizuho increased their price objective on GRAIL from $58.00 to $65.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. The Goldman Sachs Group assumed coverage on GRAIL in a research report on Friday, June 5th. They set a "neutral" rating and a $60.00 price objective for the company. TD Cowen reissued a "buy" rating on shares of GRAIL in a research note on Wednesday, July 15th. Finally, Wolfe Research assumed coverage on shares of GRAIL in a report on Tuesday, June 2nd. They issued a "peer perform" rating on the stock. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GRAIL has a consensus rating of "Hold" and an average target price of $67.78.
View Our Latest Research Report on GRAL
GRAIL Company Profile
(
Get Free Report)
GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
